Immune control of tumor stemness and therapy resistance

Cancer stem cells (CSC) are a small group of tumor cells capable of self-renewing, giving rise to new tumors, and resisting treatment, thereby causing recurrence and metastasis and representing a serious clinical problem. However, there are no approved therapies for their elimination, and limited information is available on the effects of current therapies on tumor stemness. A general consensus suggests that the anti-inflammatory and immunosuppressive tumor microenvironment promotes tumor stemness. Since we previously reported that ablation of the p50 NF-κB gene in the hematopoietic compartment (p50fl/flTie2-Cre mice) restores M1/Th1 antitumor immunity, we studied its effects on CSC and therapy resistance in models of fibrosarcoma and melanoma. Using p50fl/flTie2-Cre mice, we demonstrate that p50 NF-κB silencing impairs CSC development, their migratory capacity, and epithelial-mesenchymal transition (EMT), events known to correlate with tumor aggressiveness. Furthermore, we identify a clear antagonistic effect between Th1 and Th2 T cell polarization, with the former acting as inhibitors and the latter promoting the stemness phenotype. Consistently, while immunotherapy with anti-PD-1 promoted a marked reduction in CSC and tumor development, associated with increased levels of IFNγ, whereas concomitant administration of anti-IFNγ antibodies restored tumor growth and dissemination. Moreover, treatment with anti-IL-4 enhanced the antitumor effects of immunotherapy, reducing tumor cell stemness. Importantly, the antitumor effects of high-dose IFNγ and anti-IL-4 were confirmed in combination with doxorubicin chemotherapy. Overall, our data indicate that shifting the immune response toward a robust M1/Th1 state can significantly improve current immunotherapies and chemotherapies, by limiting CSC properties.

Authors

Institutions

Publication Details

Journal
Cancer Immunology Research
Published
2026-11-19
DOI
https://doi.org/10.1158/2326-6066.cir-26-0211
Primary Topic
Cancer Cells and Metastasis
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Immune control of tumor stemness and therapy resistance

Giovanna Chiorino, Paola Ostano, G Ballerini, Antonio Sica et al.
Cancer Immunology Research
Cancer Cells and Metastasis
article

Immune control of tumor stemness and therapy resistance

Giovanna Chiorino, Paola Ostano, G Ballerini, Antonio Sica, Anna Pastò, Francesca Guana, Francesca Maria Consonni, Marina Sironi, Mariangela Storto, Martina Incerti, Alberto Amadori
article en

Abstract

Cancer stem cells (CSC) are a small group of tumor cells capable of self-renewing, giving rise to new tumors, and resisting treatment, thereby causing recurrence and metastasis and representing a serious clinical problem. However, there are no approved therapies for their elimination, and limited information is available on the effects of current therapies on tumor stemness. A general consensus suggests that the anti-inflammatory and immunosuppressive tumor microenvironment promotes tumor stemness. Since we previously reported that ablation of the p50 NF-κB gene in the hematopoietic compartment (p50fl/flTie2-Cre mice) restores M1/Th1 antitumor immunity, we studied its effects on CSC and therapy resistance in models of fibrosarcoma and melanoma. Using p50fl/flTie2-Cre mice, we demonstrate that p50 NF-κB silencing impairs CSC development, their migratory capacity, and epithelial-mesenchymal transition (EMT), events known to correlate with tumor aggressiveness. Furthermore, we identify a clear antagonistic effect between Th1 and Th2 T cell polarization, with the former acting as inhibitors and the latter promoting the stemness phenotype. Consistently, while immunotherapy with anti-PD-1 promoted a marked reduction in CSC and tumor development, associated with increased levels of IFNγ, whereas concomitant administration of anti-IFNγ antibodies restored tumor growth and dissemination. Moreover, treatment with anti-IL-4 enhanced the antitumor effects of immunotherapy, reducing tumor cell stemness. Importantly, the antitumor effects of high-dose IFNγ and anti-IL-4 were confirmed in combination with doxorubicin chemotherapy. Overall, our data indicate that shifting the immune response toward a robust M1/Th1 state can significantly improve current immunotherapies and chemotherapies, by limiting CSC properties.

Cancer Immunology Research
Università degli Studi del Piemonte Orientale “Amedeo Avogadro” (IT), University of Padua (IT), Fondazione Edo ed Elvo Tempia (IT), The San Raffaele Telethon Institute for Gene Therapy (IT), IRCCS Humanitas Research Hospital (IT)
Cancer Cells and Metastasis
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon